Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Cipla
Deloitte
Mallinckrodt
US Army
Boehringer Ingelheim
Julphar
Farmers Insurance
Harvard Business School
AstraZeneca

Generated: February 17, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021351

« Back to Dashboard

NDA 021351 describes OXYTROL, which is a drug marketed by Allergan Sales Llc and is included in two NDAs. It is available from two suppliers. There are six patents protecting this drug and one Paragraph IV challenge. Additional details are available on the OXYTROL profile page.

The generic ingredient in OXYTROL is oxybutynin. There are sixteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the oxybutynin profile page.
Summary for 021351
Tradename:OXYTROL
Applicant:Allergan Sales Llc
Ingredient:oxybutynin
Patents:6
Therapeutic Class:Genitourinary Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 021351
Suppliers and Packaging for NDA: 021351
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
OXYTROL oxybutynin FILM, EXTENDED RELEASE;TRANSDERMAL 021351 NDA Allergan, Inc. 0023-6153 N 0023-6153-08
OXYTROL oxybutynin FILM, EXTENDED RELEASE;TRANSDERMAL 021351 NDA Actavis Pharma, Inc. 52544-920 N 52544-920-08

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:FILM, EXTENDED RELEASE;TRANSDERMALStrength3.9MG/24HR
Approval Date:Feb 26, 2003TE:ABRLD:Yes
Patent:➤ Sign UpPatent Expiration:Apr 26, 2020Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE
Patent:➤ Sign UpPatent Expiration:Apr 26, 2020Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE
Patent:➤ Sign UpPatent Expiration:Apr 26, 2020Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE

Expired US Patents for NDA 021351

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan Sales Llc OXYTROL oxybutynin FILM, EXTENDED RELEASE;TRANSDERMAL 021351-002 Feb 26, 2003 ➤ Sign Up ➤ Sign Up
Allergan Sales Llc OXYTROL oxybutynin FILM, EXTENDED RELEASE;TRANSDERMAL 021351-002 Feb 26, 2003 ➤ Sign Up ➤ Sign Up
Allergan Sales Llc OXYTROL oxybutynin FILM, EXTENDED RELEASE;TRANSDERMAL 021351-002 Feb 26, 2003 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Farmers Insurance
Moodys
Boehringer Ingelheim
Medtronic
Baxter
Dow
Citi
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot